ChristianaCare

All visitors are required to wear masks.

For COVID-19 safety, all visitors to ChristianaCare facilities and services are required to wear masks. This includes visitors who are vaccinated. Please read our visitor guidelines before arrival.

Masks required at outpatient locations; visitors and support persons limited

All visitors at outpatient locations must be masked in alignment with the masking guidelines on our visitation policy page here. Patients at ChristianaCare’s outpatient services are advised to come to their appointments alone unless a support person is absolutely needed. If a support person is needed, such as a parent, guardian or spokesperson, we highly encourage that the support person be vaccinated. Outpatient practices are not requiring vaccination or a negative COVID test for visitors at this time.

All hospital visitors required to be vaccinated or have a negative COVID-19 test.

  • Inpatients in our Christiana, Wilmington and Union hospitals may have one visitor daily between 10 a.m. and 8 p.m. The visitor must be 16 or older.
  • Patients having outpatient surgery may have one support person accompany them. Support persons must be 16 or older.
  • All visitors and surgical support people must show proof of vaccination OR a negative COVID-19 test within the prior 72 hours.

Before visiting, click here for more details about visitation.

Visit coronavirus.delaware.gov or cecilcountyhealth.org for local vaccination and testing sites.

Physicians & Staff

Bruce M. Boman, M.D., Ph.D., MSPH, FACP

Medical Director, Cancer Genetics and Stem Cell Biology

Renowned for his work in colorectal cancer, and a cancer survivor himself since 2000, Bruce M. Boman, M.D., Ph.D., is an attending physician and director for Cancer Genetics and Stem Cell Biology for ChristianaCare’s Helen F. Graham Cancer Center & Research Institute. He also represents the Graham Cancer Center as a scientist with the Center for Translational Cancer Research.

Dr. Boman’s long term career goal is to identify cancer stem cell based mechanisms that will lead to the development of new more effective, potentially even curative or preventive, treatments for cancer. Based on the emerging paradigm in oncology, effective agents will need to target cancer stem cells, which are the cells that become overpopulated during tumorigenesis and drive tumor growth. Dr. Bomann demonstrated that APC, via TCF4, regulates survivin expression and that APC, when mutant, leads to survivin overexpression and contributes to the stem cell overpopulation during colon tumorigenesis. Dr. Boman’s work also showed that survivin expression is upregulated in ApcMin/+ mice in association with Tcf4 activation and intestinal tumorigenesis. In addition, Dr. Boman’s work reported that stem cell overproduction results from increased symmetric stem cell division. Our recent research findings led to the discovery that ALDH1 is a marker for colonic stem cells and allows tracking of stem cell overpopulation during colon cancer development and isolation of cancer stem cells.

Dr. Boman’s overall hypothesis is “APC mutations that drive growth of colon cancers do so by causing stem cell overpopulation.” Dr. Boman recently published a novel model that provides a mechanism that explains how APC regulates crypt fission and, when mutant, how APC leads to abnormal crypt fission, colonic stem cell overpopulation and adenoma development.

Dr. Boman has been involved in research on APC and GI tumorigenesis for over 20 years and have vast expertise in quantitative immunohistochemical mapping of cell populations in mouse and human intestinal crypts as well as efficacy studies of chemopreventive agents using Apc Min mice. While Dr. Boman has significant experience as a laboratory chief investigating the molecular and cellular etiology of colon cancer, he is also a clinical investigator and has been integrally involved in translational efforts at all levels to advance the discoveries of cancer research to the benefit of oncology patients.

Dr. Boman served as the national princiapl investigator of the NSABP colon cancer statin prevention trial to investigate the efficacy of rosuvastatin in preventing adenomas. In addition, he has made numerous contributions to the field through publications, presentations, as a patient advocate, and service as a member on many NIH committees and study sections.

Specialties: Internal Medicine
Medical Oncology
Contact:

Helen F. Graham Cancer Center & Research Institute
4701 Ogletown-Stanton Road, Suite 2229
Newark, DE 19718
302-623-4540
302-623-4845

Education: University of Minnesota Medical School
Residency: Mayo Clinic
Fellowship: Mayo Clinic